Background: Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly blocks HR activity; but most patients eventually develop treatment resistance. We have previously reported that interleukin-1 (IL-1) inflammatory cytokine downregulates ERα and AR mRNA in HR-positive (HR + ) BCa and PCa cell lines, yet the cells can remain viable. Additionally, we identified pro-survival proteins and processes upregulated by IL-1 in HR + BCa and PCa cells, that are basally high in HR -BCa and PCa cells. Therefore, we hypothesize that IL-1 confers a conserved gene expression pattern in HR + BCa and PCa cells that mimics conserved basal gene expression patterns in HR -BCa and PCa cells to promote HR-independent survival and tumorigenicity.
diagnosis, 15-20% of BCa patients are innately ERα -(Triple Negative BCa) 5 and 10-20% of PCa patients are innately AR -(Small Cell Neuroendocrine PCa) 6 . Thus, there is a need to identify alternative therapeutic targets to ERα and AR hormone receptors.
Interleukin-1 (IL-1) is an inflammatory cytokine present in tumors that promotes tumor angiogenesis and metastasis 7 . IL-1 is elevated in BCa and PCa tumors [8] [9] [10] [11] [12] [13] and correlates with low or lost ERα or AR accumulation 10, [14] [15] [16] [17] . We discovered that IL-1 downregulates ERα and AR levels in HR + BCa and PCa cell lines concomitant with the upregulation of pro-survival proteins that are basally high in HRcell lines 18, 19 . Thus, IL-1 may select for and promote the evolution of treatment resistant cells, and our findings provide an opportunity to discover novel therapeutic targets for HR-independent BCa and PCa.
We previously used RNA sequencing (RNA-seq) to identify genes that are modulated in response to IL-1 family member, IL-1β, in the androgen-dependent AR + PCa cell line, LNCaP 18 .
Here, we performed RNA-seq for the estrogen-dependent ERα + BCa cell line, MCF7, to identify genes that are modulated in response to both major IL-1 family members, IL-1α and IL-1β. We identified 350 genes that are conserved among IL-1-treated LNCaP and MCF7 cell lines that show similar expression patterns in untreated hormone-independent AR -PC3 PCa and ERα -MDA-MB-231 BCa cell lines. Not surprisingly, canonical pathway analysis reveals that the 350 gene set encodes for proteins that activate inflammatory signaling.
We selected two genes from the 350 gene set, Sequestome-1 (SQSTM1/p62; hereinafter, p62) and SRY (Sex-Determining Region Y)-Box 9 (SOX9), for functional analysis. p62 is a multifunctional scaffold protein with well-characterized roles in autophagy and antioxidant response 20 . p62 sequesters cytotoxic protein aggregates, damaged organelles, and microbes into the autophagosome for degradation and biomolecule recycling [20] [21] [22] [23] [24] [25] [26] , binds and poly-ubiquitinates Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6), leading to the downstream activation of the pro-and anti-inflammatory transcription factor, Nuclear Factor Kappa Light Chain Enhancer of Activated B Cells (NFκB) 27, 28 , and competitively binds Kelch-Like ECH-Associated Protein 1 (KEAP1) to promote activation of the antioxidant transcription factor, Nuclear Factor (Erythroid-Derived 2)-Like 2 (NRF2) [29] [30] [31] . SOX9 is a transcription factor with many diverse functions in development 32 . For example, SOX9 promotes epithelial-to-mesenchymal (EMT) transition of neural crest 33 and endocardial endothelial 34 cells during central nervous system and cardiac development, respectively, and induces Sertoli cell differentiation during testis development 35 . Thus, the functions of p62 and SOX9 in normal cell homeostasis and development provide cancer cells with a growth advantage and promote tumorigenicity.
Specifically, we show that p62 and SOX9 are required for cell survival of HR -BCa and PCa cell lines, and therefore, are rational therapeutic targets for HR-independent BCa and PCa tumors. 37 and were quality trimmed using fastq-mcf (ea-utils/1.1.2-806) 38 . Trimmed fastq files were mapped to hg19 (UCSC version from igenomes) using TopHat 39 , duplicates were marked using picard-tools (v1.127 https://broadinstitute.github.io/picard/ ), read counts were generated using featureCounts 40 and differential expression analysis was performed using edgeR 41 . Differential gene expression lists were generated using the following cut-offs: log2 counts per million (CPM) ≥ 0, log2 fold change (FC) ≥ 0.6 or ≤ -0.6, false discovery rate (FDR) ≤ 0.05. Pathway analysis was conducted using QIAGEN's Ingenuity Pathway Analysis tool (http://www.qiagen.com/ingenuity). RNA-seq datasets generated for this study are available at GEO NCBI, accession GSE136420. resuspended in DMSO. Cells were exposed to 10 µM verteporfin or DMSO and western blotting or immunostaining for p62 oligomerization was performed to determine treatment efficacy. 
METHODS

Western blot and antibodies:
Statistical analysis:
Statistical significance was determined using unpaired student t-test. Pvalue ≤ 0.05 is considered statistically significant. Graphs are shown as the average of a minimum of n = 3 biological replicates ± standard deviation (STDEV).
RESULTS:
Identification Validation of select genes from 350 gene signature. We selected six upregulated genes (CCL20, CD68, IL-8, p62, SOX9, Zeb1) and four downregulated genes (CDK2, CXCR7, MMP16, PLK1) from our 350 gene set to validate by RT-qPCR. MCF7 and LNCaP cells were treated with 25 ng/ml IL-1α or IL-1β and MDA-MB-231 and PC3 cells were treated with vehicle control. RT-qPCR confirmed that IL-1 induces CCL20, IL-8, p62, and Zeb1 in HR + MCF7 ( Fig. 2A) and LNCaP ( Fig. 2B) cells. We detected a significant increase in CD68 and SOX9 mRNA ( Fig. 2B ) and/or protein (Fig. 3A) in IL-1-treated LNCaP cells. We did not detect an increase in SOX9 mRNA in IL-1-treated MCF7 cells ( Fig. 2A) and only a slight increase in SOX9 protein (Fig. 3A) ; and CD68
mRNA levels were only slightly induced by IL-1β in MCF7 cells ( Fig. 2A) . Finally, RT-qPCR confirmed that IL-1α and IL-1β repress CDK2, CXCR7, MMP16, and PLK1 in MCF7 and LNCaP cells (Fig. 2) .
In addition to MDA-MB-231 and PC3 cell lines, we performed RT-qPCR for basal gene expression in an additional ERα -/PR -BCa cell line, BT549, and an additional AR -PCa cell line, DU145. RT-qPCR confirmed that CCL20, CD68, IL-8, p62, and Zeb1 are basally high MDA-MB-231, BT549, PC3, and DU145 cells (Fig. 2) . SOX9 mRNA (Fig. 2) and protein (Fig. 3A) are basally high in MDA-MB-231 and PC3 cells and SOX9 protein is basally high in BT549 (Fig. 3A) ; however, SOX9 mRNA is not basally high in BT549 or DU145 (Fig. 2) . We did not find that the select IL-1-repressed genes are consistently downregulated in the HR -BCa and PCa cell lines (Fig 2) . sublines. Among the select upregulated genes we chose for RT-qPCR confirmation, p62 and SOX9 were upregulated in both treatment-resistant subline models (Supplemental Table 1 ).
Downregulation of AR or ERα/PR and target gene expression in the LNCaP 3 or MCF7 49
treatment-resistant sublines ( Supplemental Table 1 ) indicates these models evolved to survive without hormone receptor activity. Therefore, we siRNA-silenced p62 and SOX9 in HR -BCa and
PCa cell lines to determine if p62 or SOX9 are required for viability in cells that intrinsically lack hormone receptor activity. MDA-MB-231, BT549, PC3, and DU145 cells were transfected with p62 or SOX9 siRNA (Fig. 3B) and cell viability was determined on day 1 or 3 using MTT (Fig. 3C) or by recording cell number on day 1, 2, and 3 (Fig. 3D ). p62 and SOX9 siRNA are cytotoxic for the HR -BCa and PCa cell lines. Thus, p62 and SOX9 promote cell survival for cells that intrinsically lack hormone receptor activity.
Verteporfin is cytotoxic for HR -BCa and PCa cell lines. Cell that intrinsically lack hormone receptor activity are not susceptible to hormone receptor-targeting drugs, such as enzalutamide or fulvestrant. Therefore, alternative therapeutic targets are needed. The p62 inhibitor, verteporfin (Visudyne), is an FDA-approved, photosensitizing drug used with laser light to treat leaky blood vessels in the eye caused by macular degeneration. Currently, verteporfin is being tested in a Phase I clinical trial as a photosensitizer for the SpectraCure P18 photodynamic therapy system for recurrent PCa (NCT03067051). Recently, verteporfin, alone, was shown to reduce the tumor growth of subcutaneous prostate epithelial xenografts overexpressing p62 and verteporfin was able to reduce the growth of PC3 xenografts 43 . Verteporfin oligomerizes p62 ( Fig.   4A & B) , thereby preventing p62 interaction with binding partners and inhibiting p62 function 43, 50 .
We treated HR -BCa and PCa cell lines with 10 µM verteporfin for 5 days and assayed cell viability using MTT (Fig. 4C ) or by recording cell number on day 1, 3, and 5 (Fig. 4D) . Verteporfin is cytotoxic for HR -BCa and PCa cell lines.
The 350 gene signature maps to pro-tumorigenic processes in BCa and PCa cells. We used the IPA Canonical Pathways module to identify signaling pathways represented in our 350 gene set and found that the gene set encodes for proteins that are predicted to activate inflammatory signaling, including interferon (z-score = 3.2, -log p-value = 9.86E+00), IL-1 (z-score = 2, -log p-value 1.26E+00), and IL-8 signaling (z-score = 1.7, -log p-value = 4.10E+00) (Supplemental Table 1 ). We also used the IPA Regulator Effects module to predict cancerspecific networks encoded by our 350 gene set and we selected the networks in which both p62 and SOX9 were target molecules. We found three such networks in which upstream regulators CTNNB1 (z-score 2.738, p-value 5.12E-07), FGF2 (z-score 2.091, p-value 2.21E-09) and TNF (z-score 7.192, p-value 4.87E-28) were found to be activated and predicted to promote neoplasia of cells (z-score 2.699, p-value 5.20E-12 (CTNNB1)) and malignancy (z-score 2.251, p-value 1.41E-13 (FGF2, TNF)) ( Supplemental Table 1 ). Thus, the IL-1-conferred 350 gene set encodes multiple different pro-tumorigenic signaling pathways conserved among multiple different regulators.
Predicted p62 and SOX9 target molecules and functional networks in the 350 gene signature. Finally, given that siRNA-mediated loss of p62 or SOX9 are cytotoxic for HR -BCa and PCa cells, we used the IPA Upstream Regulators module to identify p62 or SOX9 predicted target molecules and functional networks in the 350 gene data set. p62 is predicted to induce CXCL2, IL15RA, IRF1, PLAT, RGCC, and RSAD2 expression (z-score = 2.449, p-value = 8.38E-05) ( Fig. 5A ; Supplemental Table 1 ) and predicted to activate HIF1A, IL-1β, NFκB1, NFKBIA, NFκB (complex), NR3C1, RELA, and SQSTM1(p62) signaling ( Fig. 5B ; Supplemental Table 1 ).
The p62-regulated genes and interactive networks are known mediators of inflammatory signaling and immunity (CXCL2, IL15RA, IRF1, RSAD2, IL-1β, NFκB, NR3C1, RELA, SQSTM1(p62)), hypoxia (HIF1A), fibrinolysis (PLAT), and cell cycle regulation (RGCC). SOX9 did not appear as a master regulator in IPA; therefore, we manually extracted its interactome from IPA and overlapped the results with the 350 gene list to identify relevant interactions. SOX9 is predicted to activate VNN1 expression and mediate FN1 and T-Cell Factor (TCF) signaling (Fig. 5C ). VNN1 functions in inflammation and immunity, FN1 promotes wound healing, and TCF interacts with βcatenin to mediate WNT signaling. Disruption of any of the processes that p62 or SOX9 are predicted to regulate or mediate as part of the 350 gene signature would be expected to reduce cell viability and may explain p62 or SOX9 siRNA-mediated cytotoxicity in BCa and PCa cells.
DISCUSSION:
IL-1 conferred 350-gene signature is enriched in genes and pathways that promote BCa and PCa survival and progression. We have previously shown that HR low/-BCa 19 and PCa 18, 42 cells are enriched when HR + cells are exposed to IL-1. Here, we sought to compare the gene expression pattern overlap between cells that lose hormone receptors in response to IL-1 to cells that are intrinsically HR -. We identified 1707 genes in BCa cells and 1900 genes in PCa cells that are upregulated by IL-1 in HR + cells and basally high in HRcells or downregulated by IL-1 in HR + cells and basally low in HRcells. To identify genes that were common to both BCa and PCa, we looked for overlapping genes and filtered down to a set of 350 genes. This conserved expression pattern represents IL-1-induced signaling in HR + BCa and PCa cells and constitutive signaling in HR -BCa and PCa cells. To gain insight in the functional output of the 350 gene set, we used IPA to predict canonical pathways. IL-1 is an inflammatory cytokine, therefore, as expected, the 350 gene set showed an enrichment for inflammatory pathways like IL-1, IL-8, IL-6, interferon, and TNF receptor signaling. Importantly, inflammatory signaling promotes BCa 9 and PCa 51 progression.
We used IPA to identify cancer-specific networks encoded by the 350 gene set that also include p62 and SOX9 as downstream target signaling molecules and found that IL-1 is predicted to activate molecular programs similar to CTNNB1, Fibroblast Growth Factor (FGF2), and Tumor Availability of data and materials: RNA-seq datasets generated for this study are available at GEO NCBI, accession GSE136420.
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